切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2008, Vol. 02 ›› Issue (05) : 27 -30. doi: 10.3877/cma.j.issn.1674-0807.2008.05.007

实验研究

p21 waf1 基因转染对乳腺癌细胞增殖活性的影响
宋洪生1, 贾伟丽2, 种瑞峰1, 李福年1,(), 刘相萍3, 王新刚1, 王宇1   
  1. 1.266003 青岛,青岛大学医学院附属医院乳腺病诊疗中心
    2.266011 青岛,青岛大学医学院附属青岛市立医院
    3.266003 青岛,青岛大学医学院附属医院分子生物实验室
  • 收稿日期:2008-04-08 出版日期:2008-10-01
  • 通信作者: 李福年

Effect of p21 waf1 gene transfection on the proliferation of human breast carcinoma cells

Hongsheng SONG1, Wei-li JIA1, Rui-feng CHONG1, Fu-nian LI,1(), Xiang-ping LIU1, Xin-gang WANG1, Yu WANG1   

  1. 1.Department of Breast Surgery, Affiliated Hospital of Qingdao University Medical College, Qingdao 266003,China
  • Received:2008-04-08 Published:2008-10-01
  • Corresponding author: Fu-nian LI
引用本文:

宋洪生, 贾伟丽, 种瑞峰, 李福年, 刘相萍, 王新刚, 王宇. p21 waf1 基因转染对乳腺癌细胞增殖活性的影响[J/OL]. 中华乳腺病杂志(电子版), 2008, 02(05): 27-30.

Hongsheng SONG, Wei-li JIA, Rui-feng CHONG, Fu-nian LI, Xiang-ping LIU, Xin-gang WANG, Yu WANG. Effect of p21 waf1 gene transfection on the proliferation of human breast carcinoma cells[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2008, 02(05): 27-30.

目的

探讨p21waf1基因转染对人乳腺癌细胞增殖活性影响及意义。

方法

应用脂质体介导法将pIRES-p21waf1真核表达载体转染入人乳腺癌MCF-7 细胞系,并得到稳定的表达。 通过荧光定量PCR、Western blot 法分别检测p21waf1基因表达及蛋白表达情况, MTT 法检测细胞增殖,流式细胞仪检测细胞周期分布。

结果

p21waf1基因转染后乳腺癌细胞生长显著受抑制,细胞周期停滞于G1 期,转染组G1 期、S 期和G2/M 期细胞比例分别为(70.52 ±3.21)%、(16.38 ±1.17)%、(9.42 ±0.98)%,未转染组则为(49.84 ±1.58)%、(36.83 ±1.36)%、(15.64 ±1.09)%,二者相比差异有统计学意义。

结论

p21waf1基因转染能够抑制人乳腺癌细胞周期演进和增殖活性,进而阻止乳腺癌的发生、发展,为乳腺癌治疗的一种新手段。

Objective

To explore the role of p21waf1 gene transfection in the proliferation of human breast carcinoma cells.

Methods

p21waf1 gene packaged with liposome was transfected into the cells of a human breast carcinoma cell line MCF-7,which stably expressing p21waf1gene. The cell growth was detected by MTT. The cell cycle pattern was assayed by flowcytometry.

Results

After transfection of pIRES-p21waf1,p21waf1 mRNA and the protein of MCF-7-p21waf1 were highly expressed compared with control. The cell growth was obviously inhibited and resulted in an accumulation of cells in G1,presenting that the proportion of the cells in G phase was obviously increased from 49.84 ±1.58% to 70.52 ±3.21%, and that of the cells in S and G2/M phases was obviously decreased from 36.83 ±1.36% to 16.38 ±1.17% and from 15.64 ±1.09% to 9.42±0.98%, respectively, as compared with the control group.

Conclusion

p21waf1gene transfection can inhibit the growth of human breast carcinoma cells and block the cell cycle, which then inhibit the genesis and development of breast cancer. So it may become a new method to treat breast cancer.

表1 MCF-7-p21waf1组和MCF-7 组p21waf1基因“△△Ct 法”相对定量结果
表2 p21waf1基因转染对乳腺癌细胞MCF-7细胞周期的影响(%)
[1]
Harper J W, Adami G R, Wei N, et al. The p21 Cdkinteracting protein Cipl is a potent inhibition of G1 cyclindependent kinases. Cell,1993,75:805 -816.
[2]
El Deity W S, Tokino T, Velculeseu V E, et al. WAF1, a potential mediator of p53 tumor suppression. Cell,1993,75:817 -825.
[3]
Shapiro G I. Cyclin-dependent kinase pathways as targets for cancer treatment.J Clin Oncol,2006,24:1770 -1783.
[4]
Landis M W,Pawlyk B S,Li T, et al. CyclinD1-dependent kinase activity in murine development and mammary tumorigenesis.Cancer Cell,2006,9:13 -12.
[5]
Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases.Trends Biochem Sci,2005,30:630 -641.
[6]
Kops G J,Weaver B A,Cleveland D W.On the road to cancer:aneuploidy and the mitotic checkpoint. Nat Rev Cancer,2005,5:773 -785.
[7]
王贵英,王士杰,李勇.细胞周期调控因子与癌发生的关系.国外医学·肿瘤学分册,2005,32,(1):14 -16.
[8]
刘晶晶.P27 的生物学功能及其在乳腺癌中的研究进展. 中华乳腺病杂志:电子版,2008,2:308 -314.
[9]
Rey M J, Fernandez P L, Jares P, et al. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol,1998,184:265 -271.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[3] 杨柳, 宋振川, 王新乐. 乳腺癌改良根治术联合背阔肌复位的临床疗效评估[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 269-273.
[4] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[5] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[6] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[7] 黄福, 王黔, 金相任, 唐云川. VEGFR2、miR-27a-5p在胃癌组织中的表达与临床病理参数及预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 558-561.
[8] 唐丹萍, 王萍, 江孟蝶, 杨晓蓉. 自体脂肪移植在乳腺癌术后乳房重建的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 582-585.
[9] 祝炜安, 林华慧, 吴建杰, 黄炯煅, 吴婷婷, 赖文杰. RDM1通过CDK4促进前列腺癌细胞进展的研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 618-625.
[10] 黄程鑫, 陈莉, 刘伊楚, 王水良, 赖晓凤. OPA1 在乳腺癌组织的表达特征及在ER阳性乳腺癌细胞中的生物学功能研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 275-284.
[11] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要